Last reviewed · How we verify
Pangramin Plus D. pteronyssinus
Pangramin Plus D. pteronyssinus is a Biologic drug developed by Miguel Blanca Gomez. It is currently in Phase 2 development.
Pangramin Plus D. pteronyssinus is used to study the efficacy and safety of subcutaneous immunotherapy in treating conditions such as Allergic Asthma, Allergic Rhinitis, and Local Allergic Rhinitis. The treatment involves a 100% concentration of D. pteronyssinus extract, which is administered as part of a randomized, double-blind, placebo-controlled study.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Pangramin Plus D. pteronyssinus |
|---|---|
| Sponsor | Miguel Blanca Gomez |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis (PHASE3)
- Subcutaneous Immunotherapy With Dermatophagoides Pteronyssinus in Local Allergic Rhinitis (PHASE2)
- Efficacy of Sublingual Immunotherapy in Polysensitized Allergic Rhinitis Patients (NA)
- Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pangramin Plus D. pteronyssinus CI brief — competitive landscape report
- Pangramin Plus D. pteronyssinus updates RSS · CI watch RSS
- Miguel Blanca Gomez portfolio CI
Frequently asked questions about Pangramin Plus D. pteronyssinus
What is Pangramin Plus D. pteronyssinus?
Who makes Pangramin Plus D. pteronyssinus?
What development phase is Pangramin Plus D. pteronyssinus in?
Related
- Manufacturer: Miguel Blanca Gomez — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing